News | May 13, 2021
Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
The agreement will help ensure wider reach and access to patients in India
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Subscribe To Our Newsletter & Stay Updated
